In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D) costs, payments, milestone fees, and royalties, with the explicit aim of bolstering its cardiometabolic disease therapy pipeline via as-yet-unexplored therapeutic modalities.

Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.

Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for brand-name prescriptions.

The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite repeatedly being pressed by Sen. Bernie Sanders (I-Vt.), chair of the

Novo Nordisk CEO explains decision to discontinue the long-acting insulin Levemir. He blamed pharmacy managers and health insurers.

During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced tough questions over the company's high prices for its blockbuster drugs Ozempic and Wegovy.

Lawmakers want to know why Americans pay so much more than other countries for weight loss drugs